Helmholtz Gemeinschaft


Green tea halts progression of cardiac transthyretin amyloidosis: an observational report

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:Green tea halts progression of cardiac transthyretin amyloidosis: an observational report
Creators Name:Kristen, A.V. and Lehrke, S. and Buss, S. and Mereles, D. and Steen, H. and Ehlermann, P. and Hardt, S. and Giannitsis, E. and Schreiner, R. and Haberkorn, U. and Schnabel, P.A. and Linke, R.P. and Roecken, C. and Wanker, E.E. and Dengler, T.J. and Altland, K. and Katus, H.A.
Abstract:BACKGROUND: Treatment options in patients with amyloidotic transthyretin (ATTR) cardiomyopathy are limited. Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea (GT), inhibits fibril formation from several amyloidogenic proteins in vitro. Thus, it might also halt progression of TTR amyloidosis. This is a single-center observational report on the effects of GT consumption in patients with ATTR cardiomopathy. METHODS: 19 patients with ATTR cardiomyopathy were evaluated by standard blood tests, echocardiography, and cardiac MRI (n = 9) before and after consumption of GT and/or green tea extracts (GTE) for 12 months. RESULTS: Five patients were not followed up for reasons of death (n = 2), discontinuation of GT/GTE consumption (n = 2), and heart transplantation (n = 1). After 12 months no increase of left ventricular (LV) wall thickness and LV myocardial mass was observed by echocardiography. In the subgroup of patients evaluated by cardiac MRI a mean decrease of LV myocardial mass (-12.5 %) was detected in all patients. This was accompanied by an increase of mean mitral annular systolic velocity of 9 % in all 14 patients. Total cholesterol (191.9 ± 8.9 vs. 172.7 ± 9.4 mg/dL; p < 0.01) and LDL cholesterol (105.8 ± 7.6 vs. 89.5 ± 8.0 mg/dL; p < 0.01) decreased significantly during the observational period. No serious adverse effects were reported by any of the participants. CONCLUSIONS: Our observation suggests an inhibitory effect of GT and/or GTE on the progression of cardiac amyloidosis. We propose a randomized placebo-controlled investigation to confirm our observation.
Keywords:Cardiomyopathy, Green Tea, Transthyretin-Derived Amyloidosis, Epigallocatechin-3-Gallate
Source:Clinical Research in Cardiology
Page Range:805-813
Date:October 2012
Official Publication:https://doi.org/10.1007/s00392-012-0463-z
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library